Precision Medicine


OncembleX – First in the world, a Novel AI technology: predicts clinical response to a specific targeted therapy.

Currently Genomic testing helps in identifying only the presence of clinically actionable mutations. However, this does not guarantee drug response to a selected targeted therapy. Alteration status of various other genes, collectively determine drug response.

OncembleX pan cancer gene panel and multi-omics platform contains clinically actionable genes, disease drivers and genes important for disease prognosis. Our report is not mere matching of an actionable mutation to an approved targteted therapy for that mutation. It takes into account:

  • Other mutations (even if non-actionable)
  • Their impact on cancer & drug pathways as well as biomarkers

Our proprietary platform analyses the collective impact of all mutations (actionable as well as non-actionable), CNVs, Splice variants & fusion on the cancer pathway and therefore the impact of the therapy

OncembleX is a new paradigm in cancer treatment – using not only well known mutations in cancer, but also a profusion of many kinds of data associated with the patient, such as genomic cross-talks, CNVs, methylations and physiological parameters – creates a holistic picture of the patient’s personalized cancer biology. This helps identify the best therapeutic intervention for the patient supported by deep biological knowledge as well as statistical evidence.

OncembleX has an optimum balance of tumor biology and data science driven approach to aid the best therapy selection for maximum clinical benefit.

NeoTox: HDRA Technology

Patient samples are screened against approved drugs for specific cancer or pan cancer drugs at therapeutic concentrations. NeoTox measures the sensitivity of patient samples to different clinically approved drugs.

  • Patient samples screened against approved drugs:
    • Chemotherapy, mAbs, & combinations
    • For specific cancer type
    • At therapeutic concentrations
  • Measures efficacy of anti-cancer therapy - Demonstrates Clinical Response
  • AI integrated lab data & generates a report with prioritised list of effective treatment options.


Vivo-PDX is an integration of Hollow Fiber Technology with Patient Derived Xenograft (PDX). Hollow Fiber-PDX is the most advanced technology adopted for clinical evaluation to measure the sensitivity of patient derived tumor cells to chemotherapy, immunotherapy and targeted therapy in mice.

  • Screened against approved drugs in mice at human equivalent therapeutic exposures
    • Chemotherapy, mAbs, & combinations
    • For specific cancer type
    • At therapeutic concentrations
  • Measures efficacy of anti-cancer therapy - Demonstrates Clinical Response
  • Tailor made therapy regimen for patients.


TK210 is the most powerful screening, prognostication and therapy monitoring biomarker assay for cancer. TK210 ELISA is a quantitative immunoassay kit for the determination of Thymidine Kinase 1 (TK1) in human blood.

TK210 test provide valuable information about progression and remission of cancer disease. As a biomarker in cancer care, it helps clinicians make timely and informed decisions about ongoing treatments.

TK210 is a critical biomarker assay for precision patient monitoring. It is a biomarker for the turnover of proliferating, or progression and/or regression of tumor cells. It saves considerable resources and avoids unnecessary side-effects in those less likely to benefit from a particular therapy.


Chemotherapy induced myelotoxicity is a common and potentially life-threatening adverse event for cancer patients. Neutropenia, thrombocytopenia, and anemia, are the most common manifestations of treatment related myelotoxicity and one of the most common reasons for dose modifications, dose delays, or discontinuation of therapy, potentially limiting therapeutic benefit.

  • Useful for patients with Myelofibrosis (on Ruxolitinib).
  • Robust assay to predict Myelotoxicity of drugs.
  • Works efficiently with bone marrow as well as blood samples.
  • Sample Requirement: Blood or Bone marrow aspirate TAT: 3 weeks


Organoids mimics the physiological features in patient tumors which is closer to clinical situation. The in-vitro sensitivity of patient tumor Organoids to anti-cancer drugs has been correlated with clinical response. OncoNoid rapidly measures the sensitivity of patient derived tumors to different clinical approved drug(s)

OncoDynamiX AI platform analysis data from OncoNoid assay and generates summary report with detailed analysis of patient tumor response to various drug (s) for a Patient specific cancer with 3D Images of tumor Live/Dead cells to help Oncologist to select the appropriate drug(s) for chemotherapy.